Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy-Reference-Cited by-同舟云学术

Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy

Published:2021-04 Issue:4 Volume:27 Page:342.e1-342.e10
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Miyao Kotaro,Terakura Seitaro,Ozawa Yukiyasu,Sawa Masashi,Kohno Akio,Kasahara Senji,Iida Hiroatsu,Ino Kazuko,Kusumoto Shigeru,Kasai Masanobu,Takami Akiyoshi,Kurahashi Shingo,Kajiguchi Tomohiro,Morishita Takanobu,Nishida Tetsuya,Murata Makoto

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference43 articles.

1. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation;Green;Biol Blood Marrow Transplant,2012

2. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study;Boeckh;Blood,1996

3. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation;Einsele;Blood,1995

4. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation;Marty;N Engl J Med,2017

5. Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French compassionate program;Robin;Biol Blood Marrow Transplant,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program;Pharmaceuticals;2023-12-18

2. Oral Versus Intravenous Anti-CMV Preemptive Strategies in Allogeneic Stem Cell Transplant Patients with CMV Reactivation: Experience from the National Center of Bone Marrow Transplantation, Tunis, Tunisia;OBM Transplantation;2023-09-12

3. Ganciclovir-induced mutations are present in a diverse spectrum of post-transplant malignancies;Genome Medicine;2022-10-31